Duke University

This year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo

Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem